GOSS
New financing, new dilution math
Gossamer Bio says it has determined the initial conversion rate for its 7.50% Convertible Senior Secured First Lien Notes due 2030 — basically, the company is putting the final numbers on a financing package that could eventually turn debt into equity. The initial rate works out to 5,347.5936 shares per $1,000 principal amount, which is the kind of number that makes cap tables sweat a little.
Why you should care
Convertible notes are a little bit like debt wearing a stock-option costume. They give the company cash now, but if the stock does well later, holders can convert and join the shareholder party. That can be good for Gossamer if the financing buys it time to keep developing seralutinib, but it also means investors have to think about dilution, leverage, and how expensive this capital really is.
The warrant piece adds another wrinkle
The company also announced the exercise price for purchase warrants tied to the deal. That matters because warrants are another potential source of future share supply — the financial equivalent of reserving extra seats at an already crowded table.
Big picture: this is not flashy drug-trial news, but financing details like these can quietly reshape the stock's upside and the amount of value existing shareholders may eventually have to share.